<DOC>
	<DOC>NCT00121381</DOC>
	<brief_summary>Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis.</brief_summary>
	<brief_title>Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Severe atopic dermatitis 5% of total body surface area (TBSA) affected Concurrent skin diseases (infections) Immunocompromised Recently received phototherapy or systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>T-cell</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>children</keyword>
	<keyword>topical corticosteroids</keyword>
</DOC>